At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Anaplastic Thyroid Cancer. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study is being done because there are currently no approved and no commonly working targeted therapies in anaplastic thyroid cancer (ATC). This is an area of urgent need for patients, not just for approved treatments but also rationally-designed clinical trials designed specifically for ATC. Patients diagnosed with anaplastic thyroid cancer have a very high likelihood of dying because of their disease. As such there is a clear need for improving therapy for ATC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnaplastic Thyroid Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartOct 2016
Primary CompletionOct 2020
Study CompletionOct 2021
TodayJul 2026
First PostedFeb 23, 2016
Enrollment StartOct 1, 2016
Primary CompletionOct 1, 2020
Study CompletionOct 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 10.4 years ago
Interventions
Pembrolizumabdrug
200 mg IV once every 3 weeks